EUCTR2006-000349-20-BE进行中（未招募）1 期
Prospective Randomized Phase-III-Trial of Paclitaxel plus Topotecan versus Topotecan plus Cisplatin in Recurrent or Persistent Cervical Carcinoma - AGO-Zervix-1
Institut fuer Frauengesundheit GmbH0 个研究点目标入组 173 人开始时间: 2008年6月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 173
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Progressive histologically confirmed carcinoma of the cervix uteri and measurable disease (RECIST) without treatment alternatives to chemotherapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Both-sided hydronephrosis, CNS-metastases or reduced general condition
研究者
相似试验
进行中（未招募）
1 期
Patients in Recurrent or Persistent Cervical CarcinomaEUCTR2006-000349-20-DEInstitut fuer Frauengesundheit GmbH326
进行中（未招募）
不适用
Prospective Randomized Phase-III-Trial of Paclitaxel plus Topotecan versus Topotecan plus Cisplatin in Recurrent or Persistent Cervical Carcinoma - AGO-Zervix-1Chemotherapeutical treatment of patients with recurrent or persistent or metastatic cervical carcinoma stage IVbEUCTR2006-000349-20-ATInstitut fuer Frauengesundheit GmbH312
进行中（未招募）
1 期
Study comparing the efficacy of paclitaxel-bevacizumab with docetaxel in 2nd or 3rd treatment of lung canceron squamous non small cell lung cancer of advanced stageMedDRA version: 14.1Level: LLTClassification code 10025062Term: Lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004524-38-FRIFCT
进行中（未招募）
不适用
A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancerEUCTR2007-005828-32-ATCECOG560
进行中（未招募）
1 期
A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancerEUCTR2007-005828-32-CZCECOG564